A Phase 2 interventional study of Pegcetacoplan in Transplant-Associated Thrombotic Microangiopathy, sponsored by Swedish Orphan Biovitrum. Completed at 14 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-28.
Sponsored by Swedish Orphan Biovitrum · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Thrombotic Microangiopathies with a site in Italy — 3 open to participants now, 3 under way, 1 of them phase 3. Thrombotic Microangiopathies · Italy.
Among the 10 studies in Thrombotic Microangiopathies with a site in Italy, this one is the only one that started in 2022, is one of 3 in phase 2, and was the 7th registered.
52 studies on the registry are indexed under Thrombotic Microangiopathies; 21 are open to participants now.
Browse Thrombotic Microangiopathies studies →3 of the 10 studies in Thrombotic Microangiopathies with a site in Italy are open now. Recruiting first, the newest first:
Fondazione Luigi Villa · Sites in Italy
Ages 12–99
Novartis Pharmaceuticals · Sites in Italy, China, France and 5 more countries
Ages 18–100
Alexion Pharmaceuticals, Inc. · Sites in Italy, United States, Australia and 14 more countries
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 19 Thrombotic Microangiopathies studies recruiting now, 13 (68%) set no upper age limit and 3 (16%) stop at 75 or younger; 9 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2022.
This study's enrollment of 12 is below the median of 40 across 24 interventional studies indexed under Thrombotic Microangiopathies.
Median enrollment 50 across the 7 interventional studies, 307 across the 3 observational. Of the 7 that completed or were terminated, 5 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 10 have an industry lead sponsor. The 6 most frequent:
Swedish Orphan Biovitrum is the lead sponsor of 82 studies on the registry; 6 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.
Swedish Orphan Biovitrum has 1 study filed under Thrombotic Microangiopathies — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Thrombotic Microangiopathies with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study was to assess pharmacokinetics (PK), pharmacodynamics (PD), efficacy, and safety of pegcetacoplan in patients with TA-TMA after HSCT.
This was a pilot study, and the sample size was based on practical rather than statistical aspects.
A total of 12 patients were to be included and treated in the study. With 12 patients included, it was estimated that 9 patients would complete at least 4 weeks of treatment, which is deemed sufficient to characterize the PK of pegcetacoplan in patients with TA-TMA to an appropriate precision. In addition, 12 patients would provide a 72 % probability to observe a response rate of at least 8 responders of the 12 patients recruited (assuming the true response rate is 70 %).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Women of , defined as any women who have experienced menarche and who are NOT permanently sterile or , must have a negative serum pregnancy test at screening and agree to use protocol-defined methods of for the duration of the study and 8 weeks after their last medicinal product (IMP) dose.
Note: Postmenopausal is defined as having had 12 consecutive months with no menses without an alternative medical cause.
Men must agree to the following for the duration of the study and 8 weeks after their last dose of IMP:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
sterile solution in stoppered glass vial given as infusion, for a total treatment duration of 12 to 16 weeks.
Drug: Pegcetacoplan
20-cc glass vials-1080 mg
Pegcetacoplan Pharmacokinetic (PK) Parameter Area Under the Curve Limited to the End of Dosing Interval (AUC0-tau)
Area under the concentration-time curve limited to the end of the dosing interval. The samples included in the calculation of AUC0-tau were collected at the following times: on dosing Days 1, 3 and 5, PK samples were taken up to 30 minutes pre-dose and at 15 minutes (± 5 min), 30 minutes (± 5 min), 1 hour (± 10 min), 4 hours (± 10 min), 8 hours (± 30 min), and 24 hours (± 30 min) post-dose as well as on Day 8 pre-dose.
Time frame: Week 1
Pegcetacoplan PK Parameter Maximal Serum Concentration (Cmax)
Maximum observed serum concentration. Determined using the samples collected post-dose on dosing Days 1, 3 and 5.
Time frame: Week 1
Pegcetacoplan PK Parameter Time to Cmax (Tmax)
Time of maximum measured serum concentration. Determined using the samples collected post-dose on dosing Days 1, 3 and 5.
Time frame: Week 1
Pegcetacoplan PK Parameter Observed Serum Concentration Pre-dose (Ctrough)
Observed serum concentration pre-dose. From Day 8 (Week 1) and onwards, PK samples were taken pre-dose at each visit.
Time frame: Week 1 up to Week 14
Absolute Levels and Change From Baseline in sC5b-9
Absolute levels and change from baseline to Week 24 in biomarker of complement activation sC5b-9
Time frame: Week 24
Absolute Levels and Change From Baseline in C3a
Absolute levels and change from baseline to Week 24 in biomarker of complement activation C3a
Time frame: Week 24
Absolute Levels and Change From Baseline in C3
Absolute levels and change from baseline to Week 24 in biomarker of complement activation C3
Time frame: Week 24
Absolute Levels and Change From Baseline in Bb
Absolute levels and change from baseline to Week 24 in biomarker of complement activation Bb
Time frame: Week 24
Absolute Levels and Change From Baseline in C4a
Absolute levels and change from baseline to Week 24 in biomarker of complement activation C4a
Time frame: Week 24
Absolute Levels and Change From Baseline in Classical Pathway (CH50)
Absolute levels and change from baseline to Week 24 in biomarker of complement activation CH50
Time frame: Week 24
Absolute Levels and Change From Baseline in Alternative Pathway (AH50)
Absolute levels and change from baseline to Week 24 in biomarker of complement activation AH50
Time frame: Week 24
Number of Participants Reaching Clinical Response at Week 24
A participant will be declared as reaching a clinical response upon improvement in laboratory markers of TMA and resolution of TMA clinical symptoms
Time frame: Week 24
Number of Participants Reaching TMA Response at Week 24
A participant will be declared as reaching TMA response upon improvement in laboratory markers of TMA
Time frame: Week 24
Overall Survival at Day 100
Survival
Time frame: Day 100 from diagnosis
Overall Survival at Week 24
Survival
Time frame: Week 24 from treatment start
Time to Clinical Response
Both clinical response sustained at week 24 and clinical response at any time during the study will be assessed.
Time frame: From treatment start to first documentation of attainment of a clinical response, up to 24 weeks
Time to TMA Response
Both TMA response sustained at week 24 and TMA response at any time during the study will be assessed.
Time frame: From treatment start to first documentation of attainment of a TMA response, up to 24 weeks
Duration of Clinical Response
Duration of clinical response sustained at week 24
Time frame: From the first observed clinical response until the response criteria is no longer fulfilled or until end of study, up to 24 weeks
Duration of TMA Response
Duration of TMA response sustained at week 24
Time frame: From the first observed TMA response until the response criteria is no longer fulfilled or until end of study, up to 24 weeks
TA-TMA Relapse at Week 24
A participant will be declared as relapsing upon appearance of laboratory markers of TMA
Time frame: Week 24
Number of Participants Reaching Clinical Response at Week 12
Number of participants reaching clinical response at week 12
Time frame: Week 12
Number of Participants Reaching TMA Response at Week 12
Number of participants reaching TMA response at week 12
Time frame: Week 12
Number of Participants With Treatment-emergent Adverse Events
Occurrence and severity of treatment-emergent adverse events.
Time frame: From treatment start to end of study, up to 6 months (8 weeks since last dose of IMP)
Change From Baseline in Platelets
Change from baseline to Week 24 in platelets
Time frame: Week 24
Change From Baseline in Hemoglobin
Change from baseline to Week 24 in hemoglobin
Time frame: Week 24
Change From Baseline in Lactate Dehydrogenase (LDH)
Change from baseline to Week 24 in LDH
Time frame: Week 24
Change From Baseline in Haptoglobin
Change from baseline to Week 24 in haptoglobin
Time frame: Week 24
Change From Baseline in Indirect Bilirubin
Change from baseline to Week 24 in indirect bilirubin
Time frame: Week 24
Change From Baseline in Serum Creatinine
Change from baseline to Week 24 in serum creatinine
Time frame: Week 24
Change From Baseline in Urine Protein/Creatinine Ratio
Change from baseline to Week 24 in urine protein/creatinine ratio
Time frame: Week 24
Change From Baseline in Systolic Blood Pressure
Change from baseline to Week 24 in systolic blood pressure. Post-dose is 30 minutes after stop of infusion. The timepoints from Week 16 onward have a single value as no infusions were administered at these study visits.
Time frame: Week 24
Change From Baseline in Diastolic Blood Pressure
Change from baseline to Week 24 in diastolic blood pressure. Post-dose is 30 minutes after stop of infusion. The timepoints from Week 16 onward have a single value as no infusions were administered at these study visits.
Time frame: Week 24
Change From Baseline in Respiratory Rate
Change from baseline to Week 24 in respiratory rate. Post-dose is 30 minutes after stop of infusion. The timepoints from Week 16 onward have a single value as no infusions were administered at these study visits.
Time frame: Week 24
Change From Baseline in Heart Rate
Change from baseline to Week 24 in heart rate. Post-dose is 30 minutes after stop of infusion. The timepoints from Week 16 onward have a single value as no infusions were administered at these study visits.
Time frame: Week 24
Change From Baseline in Temperature
Change from baseline to Week 24 in temperature. Post-dose is 30 minutes after stop of infusion. The timepoints from Week 16 onward have a single value as no infusions were administered at these study visits.
Time frame: Week 24
Number of Participants With Clinically Significant Changes in Abnormal Electrocardiogram Findings
Occurrence of clinically significant abnormal electrocardiogram findings.
Time frame: Week 24
Number of Participants With Antibodies to Pegcetacoplan Throughout Treatment and Follow-up Periods
Presence of antibodies to pegcetacoplan throughout treatment and follow-up periods.
Time frame: from treatment start to the end of the study, up to 6 months.
Number of Participants With Antibodies to Polyethylene Glycol (PEG) Throughout Treatment and Follow-up Periods
Presence of antibodies to PEG throughout treatment and follow-up periods. Baseline represents the situation at treatment start.
Time frame: from treatment start to the end of the study, up to 6 months.
Number of Participants With Treatment-emergent Anti-PEG Antibodies Throughout Treatment and Follow-up Periods
Presence of treatment-emergent anti-PEG antibodies throughout treatment and follow-up periods. Conservatively, the anti-PEG antibodies detected in a patient with a missing baseline sample have been considered as treatment-emergent.
Time frame: from treatment start to the end of the study, up to 6 months.
| Milestone | Pegcetacoplan |
|---|---|
| Started | 12 |
| Completed | 9 |
| Not completed | 3 |
| Withdrew: Adverse event | 1 |
| Withdrew: Physician decision | 1 |
| Withdrew: Death | 1 |
| Milestone | Pegcetacoplan |
|---|---|
| Started | 9 |
| Completed | 6 |
| Not completed | 3 |
| Withdrew: Death | 3 |
Area under the concentration-time curve limited to the end of the dosing interval. The samples included in the calculation of AUC0-tau were collected at the following times: on dosing Days 1, 3 and 5, PK samples were taken up to 30 minutes pre-dose and at 15 minutes (± 5 min), 30 minutes (± 5 min), 1 hour (± 10 min), 4 hours (± 10 min), 8 hours (± 30 min), and 24 hours (± 30 min) post-dose as well as on Day 8 pre-dose.
| µg*h/mL | Pegcetacoplan |
|---|---|
| Day 1-Day 3 | 14934.65 ± 4448.067 |
| Day 3-Day 5 | 20089.79 ± 5162.653 |
| Day 5-Day 8 | 36208.37 ± 10685.626 |
Maximum observed serum concentration. Determined using the samples collected post-dose on dosing Days 1, 3 and 5.
| µg/mL | Pegcetacoplan |
|---|---|
| Day 1 | 508.1 ± 134.86 |
| Day 3 | 579.6 ± 142.11 |
| Day 5 | 705.2 ± 203.04 |
Time of maximum measured serum concentration. Determined using the samples collected post-dose on dosing Days 1, 3 and 5.
| Hour | Pegcetacoplan |
|---|---|
| Day 1 | 1.0 (0.3 to 48.0) |
| Day 3 | 1.02 (0.3 to 8.5) |
| Day 5 | 1.05 (0.5 to 24.0) |
Observed serum concentration pre-dose. From Day 8 (Week 1) and onwards, PK samples were taken pre-dose at each visit.
| µg/mL | Pegcetacoplan |
|---|---|
| Week 1 | 365.22 (308.37 to 432.55) |
| Week 2 | 449.86 (344.63 to 587.23) |
| Week 3 | 585.71 (456.62 to 751.30) |
| Week 4 | 665.32 (501.51 to 882.64) |
| Week 6 | 750.82 (602.41 to 935.80) |
| Week 8 | 826.94 (655.21 to 1043.69) |
| Week 10 | 761.76 (569.21 to 1019.44) |
| Week 12 | 466.29 (112.54 to 1931.99) |
| Week 14 | 893.49 (769.46 to 1037.50) |
Absolute levels and change from baseline to Week 24 in biomarker of complement activation sC5b-9
| µg/L | Pegcetacoplan |
|---|---|
| Baseline Absolute Level | 309.2 ± 200.72 |
| Week 1 Absolute Level | 175.3 ± 81.26 |
| Week 1 Change from Baseline | -133.6 ± 176.13 |
| Week 2 Absolute Level | 152.0 ± 73.95 |
| Week 2 Change from Baseline | -163.0 ± 157.36 |
| Week 3 Absolute Level | 129.8 ± 43.38 |
| Week 3 Change from Baseline | -185.2 ± 194.18 |
| Week 4 Absolute Level | 161.6 ± 78.37 |
| Week 4 Change from Baseline | -142.1 ± 160.54 |
| Week 6 Absolute Level | 111.7 ± 37.98 |
| Week 6 Change from Baseline | -204.0 ± 217.36 |
| Week 8 Absolute Level | 148.0 ± 45.69 |
| Week 8 Change from Baseline | -168.3 ± 226.01 |
| Week 10 Absolute Level | 131.4 ± 70.60 |
| Week 10 Change from Baseline | -184.3 ± 179.44 |
| Week 12 Absolute Level | 141.2 ± 77.97 |
| Week 12 Change from Baseline | -214.0 ± 224.06 |
| Week 14 Absolute Level | 156.8 ± 65.64 |
| Week 14 Change from Baseline | -211.8 ± 211.05 |
| Week 16 Absolute Level | 158.0 ± 54.21 |
| Week 16 Change from Baseline | -210.6 ± 240.97 |
| Week 20 Absolute Level | 190.0 ± 76.28 |
| Week 20 Change from Baseline | -171.6 ± 232.00 |
| Week 24 Absolute Level | 256.0 ± 122.45 |
| Week 24 Change from Baseline | -167.8 ± 162.09 |
Occurrence and severity of treatment-emergent adverse events.
| Participants | Pegcetacoplan |
|---|---|
| Number of Participants With Treatment-emergent Adverse Events | 8 |
Change from baseline to Week 24 in platelets
| 10^9 platelets/L | Pegcetacoplan |
|---|---|
| Week 1 | 12.4 ± 24.22 |
| Week 2 | 2.8 ± 12.50 |
| Week 3 | 5.1 ± 11.20 |
| Week 4 | 18.1 ± 28.61 |
| Week 6 | 14.8 ± 21.66 |
| Week 8 | 19.6 ± 16.20 |
| Week 10 | 17.6 ± 23.01 |
| Week 12 | 13.4 ± 11.40 |
| Week 14 | 12.3 ± 13.72 |
| Week 16 | 10.6 ± 13.79 |
| Week 20 | 14.9 ± 32.23 |
| Week 24 | 22.6 ± 19.88 |
Change from baseline to Week 24 in hemoglobin
| g/L | Pegcetacoplan |
|---|---|
| Week 1 | -3.8 ± 14.30 |
| Week 2 | 8.1 ± 12.48 |
| Week 3 | 3.6 ± 14.89 |
| Week 4 | 8.0 ± 21.85 |
| Week 6 | 2.0 ± 13.20 |
| Week 8 | 9.4 ± 15.14 |
| Week 10 | 13.0 ± 15.08 |
| Week 12 | 10.6 ± 16.99 |
| Week 14 | 5.7 ± 19.77 |
| Week 16 | 7.2 ± 17.64 |
| Week 20 | 13.4 ± 11.04 |
| Week 24 | 14.0 ± 11.02 |
Change from baseline to Week 24 in LDH
| U/L | Pegcetacoplan |
|---|---|
| Week 1 | -273.9 ± 310.05 |
| Week 2 | -315.9 ± 328.13 |
| Week 3 | -348.2 ± 346.46 |
| Week 4 | -365.1 ± 363.98 |
| Week 6 | -408.0 ± 408.28 |
| Week 8 | -406.0 ± 427.49 |
| Week 10 | -428.8 ± 425.67 |
| Week 12 | -480.9 ± 405.14 |
| Week 14 | -336.3 ± 406.86 |
| Week 16 | -355.0 ± 396.77 |
| Week 20 | -242.1 ± 194.73 |
| Week 24 | -198.0 ± 235.45 |
Absolute levels and change from baseline to Week 24 in biomarker of complement activation C3a
| µg/L | Pegcetacoplan |
|---|---|
| Baseline Absolute Level | 156.9 ± 113.09 |
| Week 1 Absolute Level | 67.6 ± 70.18 |
| Week 1 Change from Baseline | -93.4 ± 120.73 |
| Week 2 Absolute Level | 126.1 ± 143.32 |
| Week 2 Change from Baseline | -27.7 ± 201.41 |
| Week 3 Absolute Level | 69.3 ± 75.08 |
| Week 3 Change from Baseline | -84.4 ± 148.81 |
| Week 4 Absolute Level | 153.6 ± 184.80 |
| Week 4 Change from Baseline | -11.9 ± 209.85 |
| Week 6 Absolute Level | 54.3 ± 31.97 |
| Week 6 Change from Baseline | -74.7 ± 61.34 |
| Week 8 Absolute Level | 73.0 ± 51.40 |
| Week 8 Change from Baseline | -57.5 ± 43.88 |
| Week 10 Absolute Level | 82.7 ± 51.19 |
| Week 10 Change from Baseline | -46.3 ± 44.74 |
| Week 12 Absolute Level | 218.4 ± 211.57 |
| Week 12 Change from Baseline | 77.8 ± 207.74 |
| Week 14 Absolute Level | 141.0 ± 173.84 |
| Week 14 Change from Baseline | -3.2 ± 198.30 |
| Week 16 Absolute Level | 150.8 ± 169.23 |
| Week 16 Change from Baseline | 6.6 ± 195.38 |
| Week 20 Absolute Level | 189.8 ± 148.22 |
| Week 20 Change from Baseline | 75.6 ± 157.49 |
| Week 24 Absolute Level | 102.4 ± 75.03 |
| Week 24 Change from Baseline | -11.5 ± 91.55 |
Absolute levels and change from baseline to Week 24 in biomarker of complement activation C3
| g/L | Pegcetacoplan |
|---|---|
| Baseline Absolute Level | 1.095 ± 0.2893 |
| Week 1 Absolute Level | 2.500 ± 0.6503 |
| Week 1 Change from Baseline | 1.313 ± 0.5038 |
| Week 2 Absolute Level | 3.095 ± 0.8883 |
| Week 2 Change from Baseline | 1.929 ± 0.7034 |
| Week 3 Absolute Level | 2.883 ± 0.9188 |
| Week 3 Change from Baseline | 1.824 ± 0.7698 |
| Week 4 Absolute Level | 3.716 ± 0.9693 |
| Week 4 Change from Baseline | 2.399 ± 0.7395 |
| Week 6 Absolute Level | 3.934 ± 0.8033 |
| Week 6 Change from Baseline | 2.777 ± 0.7718 |
| Week 8 Absolute Level | 4.238 ± 0.4511 |
| Week 8 Change from Baseline | 3.040 ± 0.3240 |
| Week 10 Absolute Level | 3.920 ± 1.0524 |
| Week 10 Change from Baseline | 2.814 ± 0.9156 |
| Week 12 Absolute Level | 4.061 ± 1.7835 |
| Week 12 Change from Baseline | 2.893 ± 1.7103 |
| Week 14 Absolute Level | 4.156 ± 1.1392 |
| Week 14 Change from Baseline | 2.957 ± 0.9774 |
| Week 16 Absolute Level | 4.320 ± 1.2352 |
| Week 16 Change from Baseline | 3.177 ± 1.2536 |
| Week 20 Absolute Level | 2.052 ± 0.9091 |
| Week 20 Change from Baseline | 0.858 ± 0.9097 |
| Week 24 Absolute Level | 1.338 ± 0.5070 |
| Week 24 Change from Baseline | 0.047 ± 0.3580 |
Absolute levels and change from baseline to Week 24 in biomarker of complement activation Bb
| mg/L | Pegcetacoplan |
|---|---|
| Baseline Absolute Level | 2.098 ± 1.5087 |
| Week 1 Absolute Level | 0.769 ± 0.4819 |
| Week 1 Change from Baseline | -1.404 ± 1.2250 |
| Week 2 Absolute Level | 0.726 ± 0.2783 |
| Week 2 Change from Baseline | -1.354 ± 1.4238 |
| Week 3 Absolute Level | 0.611 ± 0.1335 |
| Week 3 Change from Baseline | -1.469 ± 1.6091 |
| Week 4 Absolute Level | 0.749 ± 0.1857 |
| Week 4 Change from Baseline | -1.458 ± 1.6256 |
| Week 6 Absolute Level | 0.617 ± 0.1485 |
| Week 6 Change from Baseline | -1.720 ± 1.7170 |
| Week 8 Absolute Level | 0.632 ± 0.1308 |
| Week 8 Change from Baseline | -1.858 ± 1.8627 |
| Week 10 Absolute Level | 0.704 ± 0.2522 |
| Week 10 Change from Baseline | -1.633 ± 1.6250 |
| Week 12 Absolute Level | 0.746 ± 0.3340 |
| Week 12 Change from Baseline | -2.034 ± 1.6738 |
| Week 14 Absolute Level | 0.528 ± 0.1555 |
| Week 14 Change from Baseline | -1.968 ± 1.9232 |
| Week 16 Absolute Level | 0.672 ± 0.3385 |
| Week 16 Change from Baseline | -1.824 ± 1.9516 |
| Week 20 Absolute Level | 0.600 ± 0.2507 |
| Week 20 Change from Baseline | -0.966 ± 1.1270 |
| Week 24 Absolute Level | 0.746 ± 0.0631 |
| Week 24 Change from Baseline | -1.015 ± 1.1970 |
Absolute levels and change from baseline to Week 24 in biomarker of complement activation C4a
| ug/L | Pegcetacoplan |
|---|---|
| Baseline Absolute Level | 3422.9 ± 2792.23 |
| Week 1 Absolute Level | 1724.6 ± 1219.46 |
| Week 1 Change from Baseline | -1470.8 ± 3194.16 |
| Week 2 Absolute Level | 4644.1 ± 4426.51 |
| Week 2 Change from Baseline | 1263.3 ± 3370.74 |
| Week 3 Absolute Level | 4118.0 ± 4192.86 |
| Week 3 Change from Baseline | 737.2 ± 3316.77 |
| Week 4 Absolute Level | 4504.8 ± 3690.83 |
| Week 4 Change from Baseline | 811.8 ± 1763.02 |
| Week 6 Absolute Level | 3582.6 ± 3559.59 |
| Week 6 Change from Baseline | -438.7 ± 5670.06 |
| Week 8 Absolute Level | 2792.5 ± 3573.91 |
| Week 8 Change from Baseline | -987.2 ± 1295.21 |
| Week 10 Absolute Level | 2234.7 ± 2012.23 |
| Week 10 Change from Baseline | -1786.6 ± 2007.28 |
| Week 12 Absolute Level | 5171.6 ± 4735.92 |
| Week 12 Change from Baseline | 852.0 ± 4487.81 |
| Week 14 Absolute Level | 2618.2 ± 4142.08 |
| Week 14 Change from Baseline | -2269.8 ± 4901.62 |
| Week 16 Absolute Level | 1731.8 ± 1285.26 |
| Week 16 Change from Baseline | -3156.2 ± 3051.14 |
| Week 20 Absolute Level | 4007.8 ± 3648.52 |
| Week 20 Change from Baseline | -664.6 ± 3821.60 |
| Week 24 Absolute Level | 4329.2 ± 2520.61 |
| Week 24 Change from Baseline | -403.5 ± 2475.95 |
Absolute levels and change from baseline to Week 24 in biomarker of complement activation CH50
| U/mL | Pegcetacoplan |
|---|---|
| Baseline Absolute Level | 92.2 ± 17.94 |
| Week 1 Absolute Level | 99.6 ± 29.99 |
| Week 1 Change from Baseline | 7.2 ± 28.48 |
| Week 2 Absolute Level | 116.9 ± 18.98 |
| Week 2 Change from Baseline | 21.9 ± 25.30 |
| Week 3 Absolute Level | 114.9 ± 27.09 |
| Week 3 Change from Baseline | 21.0 ± 35.76 |
| Week 4 Absolute Level | 107.7 ± 21.72 |
| Week 4 Change from Baseline | 12.1 ± 13.64 |
| Week 6 Absolute Level | 114.9 ± 19.36 |
| Week 6 Change from Baseline | 25.1 ± 30.72 |
| Week 8 Absolute Level | 123.4 ± 32.40 |
| Week 8 Change from Baseline | 31.8 ± 35.78 |
| Week 10 Absolute Level | 121.1 ± 34.98 |
| Week 10 Change from Baseline | 25.5 ± 29.59 |
| Week 12 Absolute Level | 103.0 ± 45.15 |
| Week 12 Change from Baseline | 12.7 ± 42.57 |
| Week 14 Absolute Level | 127.4 ± 34.81 |
| Week 14 Change from Baseline | 35.2 ± 44.74 |
| Week 16 Absolute Level | 129.9 ± 30.42 |
| Week 16 Change from Baseline | 32.7 ± 37.69 |
| Week 20 Absolute Level | 119.6 ± 43.93 |
| Week 20 Change from Baseline | 26.3 ± 46.44 |
| Week 24 Absolute Level | 106.8 ± 51.10 |
| Week 24 Change from Baseline | 17.0 ± 73.63 |
Absolute levels and change from baseline to Week 24 in biomarker of complement activation AH50
| U/mL | Pegcetacoplan |
|---|---|
| Baseline Absolute Level | 125.8 ± 44.75 |
| Week 1 Absolute Level | 75.0 ± 57.85 |
| Week 1 Change from Baseline | -55.3 ± 49.73 |
| Week 2 Absolute Level | 65.9 ± 49.10 |
| Week 2 Change from Baseline | -47.7 ± 49.15 |
| Week 3 Absolute Level | 34.7 ± 34.38 |
| Week 3 Change from Baseline | -80.7 ± 38.62 |
| Week 4 Absolute Level | 35.4 ± 38.46 |
| Week 4 Change from Baseline | -79.9 ± 36.02 |
| Week 6 Absolute Level | 24.0 ± 40.27 |
| Week 6 Change from Baseline | -85.3 ± 38.05 |
| Week 8 Absolute Level | 23.6 ± 43.47 |
| Week 8 Change from Baseline | -85.8 ± 43.81 |
| Week 10 Absolute Level | 36.9 ± 54.84 |
| Week 10 Change from Baseline | -71.3 ± 55.56 |
| Week 12 Absolute Level | 60.6 ± 69.54 |
| Week 12 Change from Baseline | -49.5 ± 43.34 |
| Week 14 Absolute Level | 20.0 ± 41.81 |
| Week 14 Change from Baseline | -96.5 ± 45.17 |
| Week 16 Absolute Level | 35.9 ± 51.88 |
| Week 16 Change from Baseline | -84.8 ± 37.55 |
| Week 20 Absolute Level | 118.1 ± 23.74 |
| Week 20 Change from Baseline | 7.8 ± 55.02 |
| Week 24 Absolute Level | 129.4 ± 19.03 |
| Week 24 Change from Baseline | 11.5 ± 63.67 |
A participant will be declared as reaching a clinical response upon improvement in laboratory markers of TMA and resolution of TMA clinical symptoms
| Participants | Pegcetacoplan |
|---|---|
| Number of Participants Reaching Clinical Response at Week 24 | 0 |
A participant will be declared as reaching TMA response upon improvement in laboratory markers of TMA
| Participants | Pegcetacoplan |
|---|---|
| Number of Participants Reaching TMA Response at Week 24 | 2 |
Survival
| Participants | Pegcetacoplan |
|---|---|
| Overall Survival at Day 100 | 8 |
Survival
| Participants | Pegcetacoplan |
|---|---|
| Overall Survival at Week 24 | 6 |
Both clinical response sustained at week 24 and clinical response at any time during the study will be assessed.
| Weeks | Pegcetacoplan |
|---|---|
| Time to Clinical Response | NA (2.00 to NA) |
Both TMA response sustained at week 24 and TMA response at any time during the study will be assessed.
| Weeks | Pegcetacoplan |
|---|---|
| Time to TMA Response | 24.0 (6.14 to NA) |
Duration of clinical response sustained at week 24
| Weeks | Pegcetacoplan |
|---|---|
| Duration of Clinical Response | 1.6 (1.3 to 2.0) |
Duration of TMA response sustained at week 24
| Weeks | Pegcetacoplan |
|---|---|
| Duration of TMA Response | 4.0 (2.0 to 6.1) |
A participant will be declared as relapsing upon appearance of laboratory markers of TMA
| Participants | Pegcetacoplan |
|---|---|
| TA-TMA Relapse at Week 24 | 0 |
Number of participants reaching clinical response at week 12
| Participants | Pegcetacoplan |
|---|---|
| Number of Participants Reaching Clinical Response at Week 12 | 1 |
Number of participants reaching TMA response at week 12
| Participants | Pegcetacoplan |
|---|---|
| Number of Participants Reaching TMA Response at Week 12 | 2 |
Change from baseline to Week 24 in haptoglobin
| g/L | Pegcetacoplan |
|---|---|
| Week 1 | 0.070 ± 0.2280 |
| Week 2 | 0.244 ± 0.4553 |
| Week 3 | 0.179 ± 0.5054 |
| Week 4 | 0.260 ± 0.5674 |
| Week 6 | 0.590 ± 0.6451 |
| Week 8 | 0.388 ± 0.4496 |
| Week 10 | 0.578 ± 0.5832 |
| Week 12 | 0.625 ± 0.6279 |
| Week 14 | 0.620 ± 0.7013 |
| Week 16 | 0.657 ± 0.6629 |
| Week 20 | 0.686 ± 0.7459 |
| Week 24 | 0.778 ± 0.5427 |
Change from baseline to Week 24 in indirect bilirubin
| umol/L | Pegcetacoplan |
|---|---|
| Week 1 | -7.80 ± 14.213 |
| Week 2 | -9.73 ± 12.344 |
| Week 3 | -9.71 ± 14.683 |
| Week 4 | -9.87 ± 15.239 |
| Week 6 | -8.95 ± 18.202 |
| Week 8 | -11.98 ± 21.787 |
| Week 10 | -10.24 ± 18.390 |
| Week 12 | -10.71 ± 23.203 |
| Week 14 | -14.03 ± 26.164 |
| Week 16 | -13.70 ± 27.536 |
| Week 20 | -3.23 ± 9.330 |
| Week 24 | -3.65 ± 7.769 |
Change from baseline to Week 24 in serum creatinine
| umol/L | Pegcetacoplan |
|---|---|
| Week 1 | 12.14 ± 42.106 |
| Week 2 | -3.84 ± 64.131 |
| Week 3 | -14.93 ± 66.231 |
| Week 4 | -28.32 ± 101.178 |
| Week 6 | -8.80 ± 78.912 |
| Week 8 | -6.24 ± 72.867 |
| Week 10 | -7.99 ± 86.096 |
| Week 12 | -22.04 ± 64.786 |
| Week 14 | 16.13 ± 43.379 |
| Week 16 | 14.13 ± 39.711 |
| Week 20 | 17.77 ± 24.444 |
| Week 24 | 11.30 ± 17.470 |
Change from baseline to Week 24 in urine protein/creatinine ratio
| mg/mg cr | Pegcetacoplan |
|---|---|
| Week 1 | -1.0821 ± 1.90348 |
| Week 2 | 0.2738 ± 3.95639 |
| Week 3 | -0.8321 ± 1.74384 |
| Week 4 | 5.4769 ± 18.92243 |
| Week 6 | -0.7370 ± 1.25579 |
| Week 8 | -0.5807 ± 1.27999 |
| Week 10 | -0.7423 ± 1.32039 |
| Week 12 | -0.9154 ± 1.52232 |
| Week 14 | -0.9039 ± 1.54815 |
| Week 16 | -0.8121 ± 1.78436 |
| Week 20 | -0.3050 ± 1.15634 |
| Week 24 | -0.7543 ± 0.56060 |
Change from baseline to Week 24 in systolic blood pressure. Post-dose is 30 minutes after stop of infusion. The timepoints from Week 16 onward have a single value as no infusions were administered at these study visits.
| mmHg | Pegcetacoplan |
|---|---|
| Week 1 Pre-dose | -5.0 ± 20.30 |
| Week 1 Post-dose | -8.7 ± 14.24 |
| Week 2 Pre-dose | 3.9 ± 17.48 |
| Week 2 Post-dose | -0.4 ± 17.32 |
| Week 3 Pre-dose | 1.3 ± 22.46 |
| Week 3 Post-dose | -13.2 ± 9.97 |
| Week 4 Pre-dose | -7.6 ± 15.18 |
| Week 4 Post-dose | -12.0 ± 14.31 |
| Week 6 Pre-dose | -10.7 ± 16.71 |
| Week 6 Post-dose | -24.3 ± 8.66 |
| Week 8 Pre-dose | -9.1 ± 19.46 |
| Week 8 Post-dose | -13.2 ± 10.48 |
| Week 10 Pre-dose | -7.7 ± 16.02 |
| Week 10 Post-dose | -8.4 ± 17.07 |
| Week 12 Pre-dose | -10.6 ± 21.47 |
| Week 12 Post-dose | -15.0 ± 10.15 |
| Week 14 Pre-dose | -4.0 ± 17.67 |
| Week 14 Post-dose | -11.3 ± 21.96 |
| Week 16 | -13.3 ± 12.09 |
| Week 20 | -13.7 ± 12.32 |
| Week 24 | -8.3 ± 12.24 |
Change from baseline to Week 24 in diastolic blood pressure. Post-dose is 30 minutes after stop of infusion. The timepoints from Week 16 onward have a single value as no infusions were administered at these study visits.
| mmHg | Pegcetacoplan |
|---|---|
| Week 1 Pre-dose | -4.5 ± 9.21 |
| Week 1 Post-dose | -5.1 ± 7.41 |
| Week 2 Pre-dose | -2.2 ± 10.28 |
| Week 2 Post-dose | -6.0 ± 11.58 |
| Week 3 Pre-dose | -2.1 ± 11.50 |
| Week 3 Post-dose | -9.2 ± 3.43 |
| Week 4 Pre-dose | -7.6 ± 8.88 |
| Week 4 Post-dose | -7.3 ± 6.63 |
| Week 6 Pre-dose | -7.0 ± 9.42 |
| Week 6 Post-dose | -12.8 ± 7.50 |
| Week 8 Pre-dose | -7.9 ± 8.98 |
| Week 8 Post-dose | -11.3 ± 9.46 |
| Week 10 Pre-dose | -7.1 ± 8.88 |
| Week 10 Post-dose | -7.2 ± 13.20 |
| Week 12 Pre-dose | -8.6 ± 10.86 |
| Week 12 Post-dose | -10.8 ± 8.58 |
| Week 14 Pre-dose | -5.1 ± 9.04 |
| Week 14 Post-dose | -7.7 ± 16.77 |
| Week 16 | -8.3 ± 8.77 |
| Week 20 | -10.6 ± 7.28 |
| Week 24 | -13.2 ± 9.09 |
Change from baseline to Week 24 in respiratory rate. Post-dose is 30 minutes after stop of infusion. The timepoints from Week 16 onward have a single value as no infusions were administered at these study visits.
| breaths/min | Pegcetacoplan |
|---|---|
| Week 1 Pre-dose | -0.5 ± 1.69 |
| Week 1 Post-dose | -0.1 ± 0.93 |
| Week 2 Pre-dose | -0.8 ± 1.69 |
| Week 2 Post-dose | -0.3 ± 0.71 |
| Week 3 Pre-dose | 0.0 ± 1.15 |
| Week 3 Post-dose | 0.5 ± 0.55 |
| Week 4 Pre-dose | 1.0 ± 2.45 |
| Week 4 Post-dose | 1.1 ± 2.04 |
| Week 6 Pre-dose | 0.4 ± 1.67 |
| Week 6 Post-dose | 0.5 ± 1.00 |
| Week 8 Pre-dose | 0.3 ± 0.87 |
| Week 8 Post-dose | -0.2 ± 1.47 |
| Week 10 Pre-dose | 0.0 ± 1.41 |
| Week 10 Post-dose | 0.0 ± 1.58 |
| Week 12 Pre-dose | 1.4 ± 2.62 |
| Week 12 Post-dose | 0.6 ± 0.55 |
| Week 14 Pre-dose | 0.4 ± 1.27 |
| Week 14 Post-dose | 0.0 ± 1.73 |
| Week 16 | 0.7 ± 1.21 |
| Week 20 | 0.3 ± 1.25 |
| Week 24 | 0.2 ± 1.47 |
Change from baseline to Week 24 in heart rate. Post-dose is 30 minutes after stop of infusion. The timepoints from Week 16 onward have a single value as no infusions were administered at these study visits.
| bpm | Pegcetacoplan |
|---|---|
| Week 1 Pre-dose | -7.4 ± 9.91 |
| Week 1 Post-dose | -7.3 ± 8.60 |
| Week 2 Pre-dose | -4.3 ± 9.20 |
| Week 2 Post-dose | -3.6 ± 11.93 |
| Week 3 Pre-dose | -7.8 ± 8.73 |
| Week 3 Post-dose | -5.5 ± 6.06 |
| Week 4 Pre-dose | -7.3 ± 7.76 |
| Week 4 Post-dose | -8.3 ± 11.28 |
| Week 6 Pre-dose | -6.4 ± 3.78 |
| Week 6 Post-dose | -8.5 ± 4.51 |
| Week 8 Pre-dose | -9.2 ± 6.44 |
| Week 8 Post-dose | -9.3 ± 2.25 |
| Week 10 Pre-dose | -6.3 ± 6.22 |
| Week 10 Post-dose | -5.2 ± 9.96 |
| Week 12 Pre-dose | -5.8 ± 8.00 |
| Week 12 Post-dose | -11.2 ± 2.68 |
| Week 14 Pre-dose | -5.1 ± 12.33 |
| Week 14 Post-dose | 1.7 ± 7.51 |
| Week 16 | -12.3 ± 10.03 |
| Week 20 | -8.6 ± 9.57 |
| Week 24 | -6.3 ± 9.97 |
Change from baseline to Week 24 in temperature. Post-dose is 30 minutes after stop of infusion. The timepoints from Week 16 onward have a single value as no infusions were administered at these study visits.
| Celsius | Pegcetacoplan |
|---|---|
| Week 1 Pre-dose | 0.10 ± 0.671 |
| Week 1 Post-dose | -0.19 ± 0.298 |
| Week 2 Pre-dose | -0.08 ± 0.311 |
| Week 2 Post-dose | -0.13 ± 0.224 |
| Week 3 Pre-dose | -0.07 ± 0.157 |
| Week 3 Post-dose | -0.05 ± 0.197 |
| Week 4 Pre-dose | -0.03 ± 0.173 |
| Week 4 Post-dose | 0.02 ± 0.075 |
| Week 6 Pre-dose | -0.10 ± 0.235 |
| Week 6 Post-dose | 0.03 ± 0.150 |
| Week 8 Pre-dose | -0.09 ± 0.322 |
| Week 8 Post-dose | -0.04 ± 0.207 |
| Week 10 Pre-dose | 0.14 ± 0.485 |
| Week 10 Post-dose | 0.02 ± 0.277 |
| Week 12 Pre-dose | -0.05 ± 0.273 |
| Week 12 Post-dose | 0.06 ± 0.152 |
| Week 14 Pre-dose | -0.13 ± 0.256 |
| Week 14 Post-dose | -0.07 ± 0.379 |
| Week 16 | -0.14 ± 0.299 |
| Week 20 | -0.31 ± 0.430 |
| Week 24 | -0.30 ± 0.522 |
Occurrence of clinically significant abnormal electrocardiogram findings.
| Participants | Pegcetacoplan |
|---|---|
| Baseline — Normal | 3 |
| Baseline — Abnormal, not clinically significant | 9 |
| Baseline — Abnormal, clinically significant | 0 |
| Week 1 — Normal | 3 |
| Week 1 — Abnormal, not clinically significant | 8 |
| Week 1 — Abnormal, clinically significant | 0 |
| Week 2 — Normal | 4 |
| Week 2 — Abnormal, not clinically significant | 6 |
| Week 2 — Abnormal, clinically significant | 0 |
| Week 3 — Normal | 3 |
| Week 3 — Abnormal, not clinically significant | 6 |
| Week 3 — Abnormal, clinically significant | 0 |
| Week 4 — Normal | 3 |
| Week 4 — Abnormal, not clinically significant | 7 |
| Week 4 — Abnormal, clinically significant | 0 |
| Week 6 — Normal | 4 |
| Week 6 — Abnormal, not clinically significant | 5 |
| Week 6 — Abnormal, clinically significant | 0 |
| Week 8 — Normal | 4 |
| Week 8 — Abnormal, not clinically significant | 5 |
| Week 8 — Abnormal, clinically significant | 0 |
| Week 10 — Normal | 3 |
| Week 10 — Abnormal, not clinically significant | 6 |
| Week 10 — Abnormal, clinically significant | 0 |
| Week 12 — Normal | 3 |
| Week 12 — Abnormal, not clinically significant | 5 |
| Week 12 — Abnormal, clinically significant | 0 |
| Week 14 — Normal | 3 |
| Week 14 — Abnormal, not clinically significant | 4 |
| Week 14 — Abnormal, clinically significant | 0 |
| Week 16 — Normal | 2 |
| Week 16 — Abnormal, not clinically significant | 4 |
| Week 16 — Abnormal, clinically significant | 0 |
| Week 20 — Normal | 2 |
| Week 20 — Abnormal, not clinically significant | 4 |
| Week 20 — Abnormal, clinically significant | 0 |
| Week 24 — Normal | 1 |
| Week 24 — Abnormal, not clinically significant | 4 |
| Week 24 — Abnormal, clinically significant | 0 |
Presence of antibodies to pegcetacoplan throughout treatment and follow-up periods.
| Participants | Pegcetacoplan |
|---|---|
| Number of Participants With Antibodies to Pegcetacoplan Throughout Treatment and Follow-up Periods | 0 |
Presence of antibodies to PEG throughout treatment and follow-up periods. Baseline represents the situation at treatment start.
| Participants | Pegcetacoplan |
|---|---|
| Baseline — Positive | 10 |
| Baseline — Negative | 1 |
| Week 1 — Positive | 1 |
| Week 1 — Negative | 0 |
| Week 2 — Positive | 6 |
| Week 2 — Negative | 1 |
| Week 4 — Positive | 4 |
| Week 4 — Negative | 2 |
| Week 12 — Positive | 3 |
| Week 12 — Negative | 2 |
| Week 16 — Positive | 1 |
| Week 16 — Negative | 2 |
| Week 20 — Positive | 2 |
| Week 20 — Negative | 2 |
| Week 24 — Positive | 1 |
| Week 24 — Negative | 1 |
Presence of treatment-emergent anti-PEG antibodies throughout treatment and follow-up periods. Conservatively, the anti-PEG antibodies detected in a patient with a missing baseline sample have been considered as treatment-emergent.
| Participants | Pegcetacoplan |
|---|---|
| Number of Participants With Treatment-emergent Anti-PEG Antibodies Throughout Treatment and Follow-up Periods | 2 |
Collected over From the first dose of IMP and up to 8 weeks after the date of administration of the last dose of IMP, up to 24 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pegcetacoplan | 6/12 (50%) | 8/12 (66.7%) | 5/12 (41.7%) |
| Event | Pegcetacoplan |
|---|---|
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 2/12 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 1/12 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 1/12 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/12 |
| Generalised tonic-clonic seizureNervous system disorders | 1/12 |
| Haemorrhagic strokeNervous system disorders | 1/12 |
| Neuropathy peripheralNervous system disorders | 1/12 |
| Cardiac failureCardiac disorders | 1/12 |
| Cardiac failure congestiveCardiac disorders | 1/12 |
| Bronchopulmonary aspergillosisInfections and infestations | 1/12 |
| Event | Pegcetacoplan |
|---|---|
| DiarrheaGastrointestinal disorders | 3/12 |
| VomitingGastrointestinal disorders | 2/12 |
| PyrexiaGeneral disorders | 2/12 |
| Decubitus ulcerSkin and subcutaneous tissue disorders | 2/12 |
| Abdominal painGastrointestinal disorders | 1/12 |
| HemoperitoneumGastrointestinal disorders | 1/12 |
| NauseaGastrointestinal disorders | 1/12 |
| Oral painGastrointestinal disorders | 1/12 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 1/12 |
| BronchospasmRespiratory, thoracic and mediastinal disorders | 1/12 |
| Age, Categorical(Participants) | Pegcetacoplan |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 10 |
| >=65 years | 2 |
| Age, Continuous(Years) | Pegcetacoplan |
|---|---|
| Median | 50.5 (19 to 67) |
| Sex: Female, Male(Participants) | Pegcetacoplan |
|---|---|
| Female | 6 |
| Male | 6 |
| Ethnicity (NIH/OMB)(Participants) | Pegcetacoplan |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 11 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Pegcetacoplan |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 12 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | Pegcetacoplan |
|---|---|
| Greece | 7 |
| United States | 3 |
| Spain | 2 |
| Female of childbearing potential(Participants) | Pegcetacoplan |
|---|---|
| Yes | 2 |
| No (surgical sterilization) | 0 |
| No (hysterectomy) | 0 |
| No (post-menopausal more than 1 year) | 4 |
| Male method of contraception(Participants) | Pegcetacoplan |
|---|---|
| Sterilization | 0 |
| Condom | 0 |
| Abstinence | 6 |
| Other | 0 |
39 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2022 to primary completion in Dec 2024, 34 months.
Results were first posted in Nov 2025, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pegcetacoplan
Thrombotic Microangiopathies →